SGLT2 inhibitors may prevent diabetes

Dapagliflozin reduces the risk of new-onset diabetes mellitus, according to results from a pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials. The study adds to the growing list of sodium–glucose co-transporter 2 inhibitor benefits and raises the possibility of an expanded target patie...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Nephrology 2022-04, Vol.18 (4), p.203-204
Main Authors: O’Hara, Daniel V., Jardine, Meg J.
Format: Article
Language:English
Subjects:
692/163/2743/137/773
692/308/2779/777
692/4022/1585/2759/1419
692/700/565/1436/2185
Benzhydryl Compounds
Cardiovascular disease
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - prevention & control
Disease prevention
Ejection fraction
Female
Glucose
Glucosides
Heart Failure
Humans
Insulin resistance
Kidney diseases
Male
Medicine
Medicine & Public Health
Nephrology
News & Views
news-and-views
Patients
Renal Insufficiency, Chronic
Sodium
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dapagliflozin reduces the risk of new-onset diabetes mellitus, according to results from a pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials. The study adds to the growing list of sodium–glucose co-transporter 2 inhibitor benefits and raises the possibility of an expanded target patient population.
ISSN:1759-5061
1759-507X
DOI:10.1038/s41581-022-00541-8